Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2012 | Research

Effects of the tropical ginger compound,1’-acetoxychavicol acetate, against tumor promotion in K5.Stat3C transgenic mice

Authors: Vinita Batra, Zanobia Syed, Jennifer N Gill, Malari A Coburn, Patrick Adegboyega, John DiGiovanni, J Michael Mathis, Runhua Shi, John L Clifford, Heather E Kleiner-Hancock

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2012

Abstract

The purpose of the current study was to determine whether a tropical ginger derived compound 1’-acetoxychavicol acetate (ACA), suppresses skin tumor promotion in K5.Stat3C mice. In a two-week study in which wild-type (WT) and K5.Stat3C mice were co-treated with either vehicle, ACA, galanga extract, or fluocinolone acetonide (FA) and tetradecanoyl phorbol acetate (TPA), only the galanga extract and FA suppressed TPA-induced skin hyperproliferation and wet weight. None of these agents were effective at suppressing p-Tyr⁷⁰⁵Stat3 expression. However, ACA and FA showed promising inhibitory effects against skin tumorigenesis in K5.Stat3C mice. ACA also suppressed phospho-p65 NF-κB activation, suggesting a potential mechanism for its action.

Available only for authorised users

Baade PD, Balanda KP, Lowe JB: Changes in skin protection behaviors, attitudes, and sunburn: in a population with the highest incidence of skin cancer in the world. Cancer Detect Prev. 1996, 20: 566-575.PubMed

Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin. 2010, 60: 277-300. 10.3322/caac.20073.CrossRefPubMed

DiGiovanni J: Multistage carcinogenesis in mouse skin. Pharmacol Ther. 1992, 54: 63-128. 10.1016/0163-7258(92)90051-Z.CrossRefPubMed

Boutwell RK: Some Biological Aspects of Skin Carcinogenisis. Prog Exp Tumor Res. 1964, 4: 207-250.CrossRefPubMed

Slaga TJ, Fischer SM, Nelson K, Gleason GL: Studies on the mechanism of skin tumor promotion: evidence for several stages in promotion. Proc Natl Acad Sci USA. 1980, 77: 3659-3663. 10.1073/pnas.77.6.3659.PubMedCentralCrossRefPubMed

Boutwell RK: The function and mechanism of promoters of carcinogenesis. CRC Crit Rev Toxicol. 1974, 2: 419-443.CrossRefPubMed

Yuspa SH, Poirier MC: Chemical carcinogenesis: from animal models to molecular models in one decade. Adv Cancer Res. 1988, 50: 25-70.CrossRefPubMed

Chan KS, Carbajal S, Kiguchi K, Clifford J, Sano S, DiGiovanni J: Epidermal growth factor receptor-mediated activation of Stat3 during multistage skin carcinogenesis. Cancer Res. 2004, 64: 2382-2389. 10.1158/0008-5472.CAN-03-3197.CrossRefPubMed

Ihle JN: The Stat family in cytokine signaling. Curr Opin Cell Biol. 2001, 13: 211-217. 10.1016/S0955-0674(00)00199-X.CrossRefPubMed

10.

Chan KS, Sano S, Kiguchi K, Anders J, Komazawa N, Takeda J, DiGiovanni J: Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest. 2004, 114: 720-728.PubMedCentralCrossRefPubMed

11.

Sano S, Chan KS, Carbajal S, Clifford J, Peavey M, Kiguchi K, Itami S, Nickoloff BJ, DiGiovanni J: Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med. 2005, 11: 43-49. 10.1038/nm1162.CrossRefPubMed

12.

Sano S, Chan KS, Kira M, Kataoka K, Takagi S, Tarutani M, Itami S, Kiguchi K, Yokoi M, Sugasawa K, Mori T, Hanaoka F, Takeda J, DiGiovanni J: Signal transducer and activator of transcription 3 is a key regulator of keratinocyte survival and proliferation following UV irradiation. Cancer Res. 2005, 65: 5720-5729. 10.1158/0008-5472.CAN-04-4359.CrossRefPubMed

13.

Yin W, Cheepala S, Roberts JN, Syson-Chan K, DiGiovanni J, Clifford JL: Active Stat3 is required for survival of human squamous cell carcinoma cells in serum-free conditions. Mol Cancer. 2006, 5: 15-10.1186/1476-4598-5-15.PubMedCentralCrossRefPubMed

14.

Kataoka K, Kim DJ, Carbajal S, Clifford J, DiGiovanni J: Stage-specific disruption of Stat3 demonstrates a direct requirement during both the initiation and promotion stages of mouse skin tumorigenesis. Carcinogenesis. 2008, 29: 1108-1114. 10.1093/carcin/bgn061.PubMedCentralCrossRefPubMed

15.

Syed Z, Cheepala SB, Gill JN, Stein J, Nathan CA, Digiovanni J, Batra V, Adegboyega P, Kleiner HE, Clifford JL: All-trans retinoic acid suppresses Stat3 signaling during skin carcinogenesis. Cancer Prev Res (Phila Pa). 2009, 2: 903-911. 10.1158/1940-6207.CAPR-09-0041.CrossRef

16.

Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE: Stat3 as an oncogene. Cell. 1999, 98: 295-303. 10.1016/S0092-8674(00)81959-5.CrossRefPubMed

17.

Chan KS, Sano S, Kataoka K, Abel E, Carbajal S, Beltran L, Clifford J, Peavey M, Shen J, Digiovanni J: Forced expression of a constitutively active form of Stat3 in mouse epidermis enhances malignant progression of skin tumors induced by two-stage carcinogenesis. Oncogene. 2008, 27: 1087-1094. 10.1038/sj.onc.1210726.CrossRefPubMed

18.

Karin M: Nuclear factor-kappaB in cancer development and progression. Nature. 2006, 441: 431-436. 10.1038/nature04870.CrossRefPubMed

19.

Aggarwal S, Takada Y, Singh S, Myers JN, Aggarwal BB: Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kappaB signaling. Int J Cancer. 2004, 111: 679-692. 10.1002/ijc.20333.CrossRefPubMed

20.

Loercher A, Lee TL, Ricker JL, Howard A, Geoghegen J, Chen Z, Sunwoo JB, Sitcheran R, Chuang EY, Mitchell JB, Baldwin AS, Van Waes C: Nuclear factor-kappaB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res. 2004, 64: 6511-6523. 10.1158/0008-5472.CAN-04-0852.CrossRefPubMed

21.

Kobielak A, Fuchs E: Links between alpha-catenin, NF-kappaB, and squamous cell carcinoma in skin. Proc Natl Acad Sci USA. 2006, 103: 2322-2327. 10.1073/pnas.0510422103.PubMedCentralCrossRefPubMed

22.

Mukhtar H, Agarwal R: Skin cancer chemoprevention. J Investig Dermatol Symp Proc. 1996, 1: 209-214.PubMed

23.

Gupta S, Mukhtar H: Chemoprevention of skin cancer: current status and future prospects. Cancer Metastasis Rev. 2002, 21: 363-380. 10.1023/A:1021275330385.CrossRefPubMed

24.

Bickers DR, Athar M: Novel approaches to chemoprevention of skin cancer. J Dermatol. 2000, 27: 691-695.CrossRefPubMed

25.

Kondo A, Ohigashi H, Murakami A, Suratwadee J, Koshimizu K: 1'-Acetoxychavicol Acetate as a Potent inhibitor of Tumor Promoter-induced Epstein-Barre Virus Activation from Languas galanga, a Traditional Thai Condiment. Biosci. Biotech. Biochem. 1993, 57: 1344-1345. 10.1271/bbb.57.1344.CrossRef

26.

Murakami A, Kuki W, Takahashi Y, Yonei H, Nakamura Y, Ohto Y, Ohigashi H, Koshimizu K: Auraptene, a citrus coumarin, inhibits 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion in ICR mouse skin, possibly through suppression of superoxide generation in leukocytes. Jpn J Cancer Res. 1997, 88: 443-452. 10.1111/j.1349-7006.1997.tb00402.x.CrossRefPubMed

27.

Murakami A, Ohura S, Nakamura Y, Koshimizu K, Ohigashi H: 1'-Acetoxychavicol acetate, a superoxide anion generation inhibitor, potently inhibits tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in ICR mouse skin. Oncology. 1996, 53: 386-391. 10.1159/000227593.CrossRefPubMed

28.

Tanaka T, Kawabata K, Kakumoto M, Matsunaga K, Mori H, Murakami A, Kuki W, Takahashi Y, Yonei H, Satoh K, Hara A, Maeda M, Ota T, Odashima S, Koshimizu K, Ohigashi H: Chemoprevention of 4-nitroquinoline 1-oxide-induced oral carcinogenesis by citrus auraptene in rats. Carcinogenesis. 1998, 19: 425-431. 10.1093/carcin/19.3.425.CrossRefPubMed

29.

Ohnishi M, Tanaka T, Makita H, Kawamori T, Mori H, Satoh K, Hara A, Murakami A, Ohigashi H, Koshimizu K: Chemopreventive effect of a xanthine oxidase inhibitor, 1'-acetoxychavicol acetate, on rat oral carcinogenesis. Jpn J Cancer Res. 1996, 87: 349-356. 10.1111/j.1349-7006.1996.tb00229.x.CrossRefPubMed

30.

Tanaka T, Kawabata K, Kakumoto M, Makita H, Matsunaga K, Mori H, Satoh K, Hara A, Murakami A, Koshimizu K, Ohigashi H: Chemoprevention of azoxymethane-induced rat colon carcinogenesis by a xanthine oxidase inhibitor, 1'-acetoxychavicol acetate. Jpn J Cancer Res. 1997, 88: 821-830. 10.1111/j.1349-7006.1997.tb00457.x.CrossRefPubMed

31.

Tanaka T, Kawabata K, Kakumoto M, Hara A, Murakami A, Kuki W, Takahashi Y, Yonei H, Maeda M, Ota T, Odashima S, Yamane T, Koshimizu K, Ohigashi H: Citrus auraptene exerts dose-dependent chemopreventive activity in rat large bowel tumorigenesis: the inhibition correlates with suppression of cell proliferation and lipid peroxidation and with induction of phase II drug-metabolizing enzymes. Cancer Res. 1998, 58: 2550-2556.PubMed

32.

Ito K, Nakazato T, Murakami A, Yamato K, Miyakawa Y, Yamada T, Hozumi N, Ohigashi H, Ikeda Y, Kizaki M: Induction of apoptosis in human myeloid leukemic cells by 1'-acetoxychavicol acetate through a mitochondrial- and Fas-mediated dual mechanism. Clin Cancer Res. 2004, 10: 2120-2130. 10.1158/1078-0432.CCR-1142-03.CrossRefPubMed

33.

Moffatt J, Hashimoto M, Kojima A, Kennedy DO, Murakami A, Koshimizu K, Ohigashi H, Matsui-Yuasa I: Apoptosis induced by 1'-acetoxychavicol acetate in Ehrlich ascites tumor cells is associated with modulation of polyamine metabolism and caspase-3 activation. Carcinogenesis. 2000, 21: 2151-2157. 10.1093/carcin/21.12.2151.CrossRefPubMed

34.

Kawabata K, Tanaka T, Yamamoto T, Ushida J, Hara A, Murakami A, Koshimizu K, Ohigashi H, Stoner GD, Mori H: Suppression of N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis by dietary feeding of 1'-acetoxychavicol acetate. Jpn J Cancer Res. 2000, 91: 148-155. 10.1111/j.1349-7006.2000.tb00926.x.CrossRefPubMed

35.

Nakamura Y, Murakami A, Ohto Y, Torikai K, Tanaka T, Ohigashi H: Suppression of tumor promoter-induced oxidative stress and inflammatory responses in mouse skin by a superoxide generation inhibitor 1'-acetoxychavicol acetate. Cancer Res. 1998, 58: 4832-4839.PubMed

36.

Campbell CT, Prince M, Landry GM, Kha V, Kleiner HE: Pro-apoptotic effects of 1'-acetoxychavicol acetate in human breast carcinoma cells. Toxicol Lett. 2007, 173: 151-160. 10.1016/j.toxlet.2007.07.008.CrossRefPubMed

37.

Ichikawa H, Takada Y, Murakami A, Aggarwal BB: Identification of a novel blocker of I kappa B alpha kinase that enhances cellular apoptosis and inhibits cellular invasion through suppression of NF-kappa B-regulated gene products. J Immunol. 2005, 174: 7383-7392.CrossRefPubMed

38.

Batra: Effects of chemopreventive agents in 12-O-tetradecanoylphorbol-13-acetate (TPA) treated mouse epidermis. 2007, Louisiana State University-Health Sciences Center, Shreveport, Shreveport, 191-Pharmacology, Toxicology & Neuroscience

39.

Li Y, Wheeler DL, Alters W, Chaiswing L, Verma AK, Oberley TD: Early epidermal destruction with subsequent epidermal hyperplasia is a unique feature of the papilloma-independent squamous cell carcinoma phenotype in PKCepsilon overexpressing transgenic mice. Toxicol Pathol. 2005, 33: 684-694. 10.1080/01926230500323441.CrossRefPubMed

40.

Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976, 72: 248-254. 10.1016/0003-2697(76)90527-3.CrossRefPubMed

41.

Stanley PL, Steiner S, Havens M, Tramposch KM: Mouse skin inflammation induced by multiple topical applications of 12-O-tetradecanoylphorbol-13-acetate. Skin Pharmacol. 1991, 4: 262-271. 10.1159/000210960.CrossRefPubMed

42.

Aziz MH, Manoharan HT, Verma AK: Protein kinase C epsilon, which sensitizes skin to sun's UV radiation-induced cutaneous damage and development of squamous cell carcinomas, associates with Stat3. Cancer Res. 2007, 67: 1385-1394. 10.1158/0008-5472.CAN-06-3350.CrossRefPubMed

43.

Murakami A, Toyota K, Ohura S, Koshimizu K, Ohigashi H: Structure-activity relationships of (1'S)-1'-acetoxychavicol acetate, a major constituent of a southeast Asian condiment plant Languas galanga, on the inhibition of tumor-promoter-induced Epstein-Barr virus activation. J Agric Food Chem. 2000, 48: 1518-1523. 10.1021/jf990528r.CrossRefPubMed

44.

Sporn MB, Dunlop NM, Newton DL, Smith JM: Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc. 1976, 35: 1332-1338.PubMed

45.

Schwarz JA, Viaje A, Slaga TJ: Fluocinolone acetonide: a potent inhibitor of mouse skin tumor promotion and epidermal DNA synthesis. Chem Biol Interact. 1977, 17: 331-347. 10.1016/0009-2797(77)90096-5.CrossRefPubMed

46.

Kleiner-Hancock HE, Shi R, Remeika A, Robbins D, Prince M, Gill JN, Syed Z, Adegboyega P, Mathis JM, Clifford JL: Effects of ATRA combined with citrus and ginger-derived compounds in human SCC xenografts. BMC Cancer. 2010, 10: 394-10.1186/1471-2407-10-394.PubMedCentralCrossRefPubMed

47.

Cheepala SB, Yin W, Syed Z, Gill JN, McMillian A, Kleiner HE, Lynch M, Loganantharaj R, Trutschl M, Cvek U, Clifford JL: Identification of the B-Raf/Mek/Erk MAP kinase pathway as a target for all-trans retinoic acid during skin cancer promotion. Mol Cancer. 2009, 8: 27-10.1186/1476-4598-8-27.PubMedCentralCrossRefPubMed

Title: Effects of the tropical ginger compound,1’-acetoxychavicol acetate, against tumor promotion in K5.Stat3C transgenic mice
Authors: Vinita Batra
Zanobia Syed
Jennifer N Gill
Malari A Coburn
Patrick Adegboyega
John DiGiovanni
J Michael Mathis
Runhua Shi
John L Clifford
Heather E Kleiner-Hancock
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2012
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/1756-9966-31-57

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2012

Over-expression of BMPR-IB reduces the malignancy of glioblastoma cells by upregulation of p21 and p27Kip1

Up-regulation of hypoxia inducible factor-1α by cobalt chloride correlates with proliferation and apoptosis in PC-2 cells

DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer

5-Fluorouracil induces apoptosis in rat cardiocytes through intracellular oxidative stress

Whole blood transcriptome correlates with treatment response in nasopharyngeal carcinoma

Clinicopathological significance of non-small cell lung cancer with high prevalence of Oct-4 tumor cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer